Pharmaceutical giant Lupin Ltd announced on Friday, March 7, that it has launched Rivaroxaban Tablets USP, 2.5 mg, in the United States market following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA).
The newly launched medication is a generic equivalent of Janssen Pharmaceuticals' Xarelto® 2.5 mg, a widely prescribed anticoagulant. According to IQVIA MAT data for January 2025, Rivaroxaban tablets USP, 2.5 mg, generated estimated annual sales of $446 million in the US market, representing a significant commercial opportunity for Lupin.
Therapeutic Applications and Clinical Significance
Rivaroxaban 2.5 mg is indicated for reducing the risk of major cardiovascular events in patients with coronary artery disease (CAD). The drug also helps reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including those who have undergone lower extremity revascularization due to symptomatic PAD.
This launch expands treatment options for patients with these serious cardiovascular conditions, which remain leading causes of morbidity and mortality worldwide. Anticoagulant therapy plays a crucial role in preventing life-threatening complications in these high-risk patient populations.
Market Position and Strategic Importance
With this launch, Lupin strengthens its presence in the high-value anticoagulant market, diversifying its cardiovascular portfolio in the United States. The company's ability to successfully navigate the regulatory pathway for complex generics demonstrates its technical capabilities and commitment to expanding access to important medications.
"This approval represents an important milestone in our ongoing efforts to bring affordable treatment options to patients in the United States," a Lupin spokesperson stated in the regulatory filing.
Financial Performance Context
The launch comes amid strong financial performance for the Mumbai-headquartered pharmaceutical company. For the third quarter of fiscal year 2025, Lupin reported a profit after tax of ₹8,589 crore, marking a 38.8% increase from the previous year's ₹6,187 crore.
Total revenue from operations surged 102.7% to ₹57,677 crore compared to ₹51,974 crore in the same period last fiscal year. The company's EBITDA (earnings before interest, tax, depreciation, and amortization) increased by 25.1% to ₹14,096 crore, with the EBITDA margin expanding to 21.1%.
Company Profile and Global Footprint
Lupin has established itself as a global pharmaceutical company with operations across 100 markets worldwide. The company specializes in a diverse range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
The successful launch of Rivaroxaban tablets in the US market aligns with Lupin's strategic focus on expanding its presence in key therapeutic areas and major pharmaceutical markets. The company continues to leverage its research and development capabilities to bring important generic medications to market, potentially increasing accessibility and affordability for patients.
Market response to the announcement was positive, with Lupin shares closing at ₹2,029.00 on the National Stock Exchange (NSE), up 0.52%, though the drug launch was announced after market hours.
